Pfizer Valuation

Is 500680 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500680 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500680 (₹4346.7) is trading above our estimate of fair value (₹1485.35)

Significantly Below Fair Value: 500680 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500680?

Other financial metrics that can be useful for relative valuation.

500680 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.2x
Enterprise Value/EBITDA29.2x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does 500680's PE Ratio compare to its peers?

The above table shows the PE ratio for 500680 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.9x
500674 Sanofi India
29.1x9.5%₹175.4b
APLLTD Alembic Pharmaceuticals
31.9x15.6%₹188.2b
LAURUSLABS Laurus Labs
114.1x49.3%₹214.4b
SUVENPHAR Suven Pharmaceuticals
44.6x15.4%₹165.5b
500680 Pfizer
39.6x14.5%₹199.0b

Price-To-Earnings vs Peers: 500680 is good value based on its Price-To-Earnings Ratio (39.6x) compared to the peer average (54.9x).


Price to Earnings Ratio vs Industry

How does 500680's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 500680 is expensive based on its Price-To-Earnings Ratio (39.6x) compared to the Indian Pharmaceuticals industry average (32.3x).


Price to Earnings Ratio vs Fair Ratio

What is 500680's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500680 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.6x
Fair PE Ratio31.4x

Price-To-Earnings vs Fair Ratio: 500680 is expensive based on its Price-To-Earnings Ratio (39.6x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 500680 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹4,346.70
₹4,720.33
+8.6%
8.0%₹5,036.00₹4,190.00n/a3
Mar ’25₹4,583.85
₹4,720.33
+3.0%
8.0%₹5,036.00₹4,190.00n/a3
Feb ’25₹4,586.15
₹4,526.33
-1.3%
7.5%₹4,954.00₹4,125.00n/a3
Jan ’25₹4,260.75
₹4,352.25
+2.1%
9.7%₹4,954.00₹3,830.00n/a4
Dec ’24₹4,098.35
₹4,441.80
+8.4%
9.4%₹4,954.00₹3,830.00n/a5
Nov ’24₹3,876.70
₹4,441.80
+14.6%
9.4%₹4,954.00₹3,830.00n/a5
Oct ’24₹3,862.30
₹4,441.80
+15.0%
9.4%₹4,954.00₹3,830.00n/a5
Sep ’24₹3,816.20
₹4,441.80
+16.4%
9.4%₹4,954.00₹3,830.00n/a5
Aug ’24₹4,018.00
₹4,460.00
+11.0%
8.6%₹4,800.00₹3,830.00n/a5
Jul ’24₹3,776.80
₹4,460.00
+18.1%
8.6%₹4,800.00₹3,830.00n/a5
Jun ’24₹3,811.60
₹4,595.00
+20.6%
4.9%₹4,800.00₹4,200.00n/a5
May ’24₹3,751.65
₹4,988.40
+33.0%
8.3%₹5,500.00₹4,505.00n/a5
Apr ’24₹3,463.90
₹4,988.40
+44.0%
8.3%₹5,500.00₹4,505.00n/a5
Mar ’24₹3,810.45
₹4,988.40
+30.9%
8.3%₹5,500.00₹4,505.00₹4,583.855
Feb ’24₹3,810.95
₹5,179.40
+35.9%
6.9%₹5,500.00₹4,505.00₹4,586.155
Jan ’24₹4,427.55
₹5,297.40
+19.6%
8.2%₹5,790.00₹4,505.00₹4,260.755
Dec ’23₹4,555.45
₹5,297.40
+16.3%
8.2%₹5,790.00₹4,505.00₹4,098.355
Nov ’23₹4,397.50
₹5,225.40
+18.8%
7.5%₹5,550.00₹4,480.00₹3,876.705
Oct ’23₹4,261.50
₹5,225.40
+22.6%
7.5%₹5,550.00₹4,480.00₹3,862.305
Sep ’23₹4,242.75
₹5,225.40
+23.2%
7.5%₹5,550.00₹4,480.00₹3,816.205
Aug ’23₹4,219.80
₹5,511.80
+30.6%
12.4%₹6,800.00₹4,810.00₹4,018.005
Jul ’23₹4,112.75
₹5,201.25
+26.5%
4.8%₹5,500.00₹4,810.00₹3,776.804
Jun ’23₹4,291.25
₹5,521.00
+28.7%
12.3%₹6,800.00₹4,810.00₹3,811.605
May ’23₹4,380.85
₹5,647.00
+28.9%
10.3%₹6,800.00₹5,271.00₹3,751.655
Apr ’23₹4,354.00
₹5,749.25
+32.0%
10.7%₹6,800.00₹5,314.00₹3,463.904
Mar ’23₹4,401.95
₹5,749.25
+30.6%
10.7%₹6,800.00₹5,314.00₹3,810.454

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.